Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade B 91.15 -0.89% -0.82
RARE closed down 0.89 percent on Monday, October 19, 2020, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical RARE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
20 DMA Support Bullish -2.79%
180 Bullish Setup Bullish Swing Setup -2.79%
Slingshot Bullish Bullish Swing Setup -2.79%
Upper Bollinger Band Walk Strength -2.79%
Multiple of Ten Bullish Other -2.79%
Overbought Stochastic Strength -2.79%
Slingshot Bullish Bullish Swing Setup -1.66%
New 52 Week High Strength -1.66%
Upper Bollinger Band Walk Strength -1.66%
Older End-of-Day Gignals for RARE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 7 hours ago
Up 1% about 7 hours ago
Trending on StockTwits about 16 hours ago
Trending on StockTwits 1 day ago
Trending on StockTwits 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases

Is RARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 99.25
52 Week Low 31.99
Average Volume 323,170
200-Day Moving Average 69.01
50-Day Moving Average 84.89
20-Day Moving Average 88.56
10-Day Moving Average 93.44
Average True Range 4.36
ADX 25.13
+DI 21.97
-DI 16.40
Chandelier Exit (Long, 3 ATRs ) 86.18
Chandelier Exit (Short, 3 ATRs ) 90.63
Upper Bollinger Band 99.40
Lower Bollinger Band 77.72
Percent B (%b) 0.62
BandWidth 24.47
MACD Line 3.07
MACD Signal Line 2.92
MACD Histogram 0.1518
Fundamentals Value
Market Cap 5.52 Billion
Num Shares 60.6 Million
EPS -7.01
Price-to-Earnings (P/E) Ratio -13.00
Price-to-Sales 34.59
Price-to-Book 8.23
PEG Ratio -0.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 94.98
Resistance 3 (R3) 95.19 94.13 94.34
Resistance 2 (R2) 94.13 93.16 94.02 94.12
Resistance 1 (R1) 92.64 92.55 92.11 92.43 93.91
Pivot Point 91.58 91.58 91.32 91.47 91.58
Support 1 (S1) 90.09 90.61 89.56 89.88 88.39
Support 2 (S2) 89.03 90.00 88.92 88.18
Support 3 (S3) 87.54 89.03 87.96
Support 4 (S4) 87.33